Skip to main content

Increasing Prevalence of Chronic Diseases to Augment the Hospital Pharmaceuticals Market Growth

 


Hospital pharmaceuticals consist of medicines purchased for hospitals, healthcare centers to be administered to patients during hospitalization. Hospital pharmaceuticals include therapeutic and critical care drugs applied in infections, neurology, urology, cardiology, hematology, dermatology, respiratory system, musculoskeletal system, sensory organs, alimentary tract and metabolism, and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications.

Market Dynamics:

Increasing incidence or prevalence of chronic diseases across the world, especially in the North America, is expected to propel the growth of the hospital pharmaceuticals market. For instance, chronic diseases such as diabetes, cancer, and heart disease, are the leading causes of death and disability in the United States, according to the Centers for Disease Control and Prevention (CDC). They are also leading drivers of the nation's $3.8 trillion in annual health care costs.

Moreover, the emergence of COVID-19 (SARS-CoV-2) is expected to augment the growth of the hospital pharmaceuticals market. For instance, in February 2021, Facing the challenge of a fast-paced and complex rollout of COVID-19 vaccines, Pennsylvania Hospital deployed radio frequency identification (RFID) technology to track the status of every vial that is removed from an ultra-freezer, then transported to the vaccination clinic, and sometimes returned to refrigeration, all while ensuring no vial expires before reaching a patient's arm.

Increasing demand for hospital pharmaceuticals and increasing spending on pharmaceuticals is also expected to fuel the growth of the hospital pharmaceuticals market. However,

Competitive Analysis:

Major players operating in the hospital pharmaceuticals market are Eli Lilly and Company, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline Plc., AstraZeneca Plc., Pfizer, Inc., Novartis AG, and Bayer AG.

Major players in the market are adopting various strategies, such as partnership, collaboration, product launch, etc., to enhance their market presence. For instance, in February 2021, Recce Pharma Ltd. formalized an agreement with Fiona Stanley Hospital for a Phase 1/2 clinical trial to assess the potential of RECCE 327’s new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections.

In February 2021, Algernon Pharmaceuticals provided an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.

In February 2021, Valeo Pharma and Ingenew Pharma announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's clinical trial, "The Hesperidin Coronavirus Study".

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Disposable Infusion Extension Lines Market Is Growing Rapidly Due To Rise in Number of Chronic Disease Cases All Over the World

  Overview: The disposable infusion extension lines are an important part of insulin pump therapy. It allows continuous insulin delivery. It is also known as a butterfly vein set or a scalp vein set. The device consists of a hypodermic needle, flexible wings, and small bore tubing. The extension line is then attached to the insulin pump or other devices. The disposable infusion extension line market is dominated by North America. The rising incidence of road accidents is a major driving factor for the growth of the market in this region. Disposable Infusion Extension Lines Market Drivers:- Major driver for growth of the global disposable infusion extension lines market is increasing blood donation campaigns. According to a survey conducted by World Health Organization (WHO), in 2015, more than 51.2 million people in India donate blood annually. The survey also reports that the need for blood donation camps have increased due to rise in road accidents. According to a survey c...
Post a Comment
Read more

PACS and RIS Market To Witness Substantial Growth Due To Growing Popularity of PACS around the World

  Overview: A PACS system is a database of medical images and other medical information. It is generally stored in an RIS, though radiologists may choose to view the results directly in PACS. Cloud PACS solutions, however, allow radiologists to access even more information. Moreover, many providers boast of being able to integrate PACS with RIS. However, they are unable to quantify the integration time. RIS and PACS solutions are designed to facilitate interoperability among imaging devices. This is done by creating a standardized communication interface based on DICOM standards. The RIS acts as a master system that provides image management and move control functions.   Market Dynamics: The popularity of PACS is growing all over the world and this is anticipated to propel growth of the global PACS and RIS market over the forecast period. PACS help to reduce the physical as well as time barriers linked to regular film-based retrieval, display and distribution of images. ...
Post a Comment
Read more

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 
Post a Comment
Read more